Exacerbation rate in COPD reduced by RoflumilastIn a large 12-month randomized trial, Roflumilast was found effective for improving lung function and prevent exacerbations in patients with COPD with chronic bronchitis and severe airflow obstruction.

Dr. Andrew McIvor said at the annual meeting of the American College of Chest Physicians that results of the 1,568-patient, double-blind, placebo-controlled study known as the M2-125 trial indicate that roflumilast is an important potential advance in the treatment of a subset of patients with COPD.

Dr. McIvor of St. Joseph’s Healthcare Hamilton (Ont.) explained that Roflumilast (Daxas) is an investigational selective phosphodiesterase 4 inhibitor that can target the inflammation that is a hallmark of the disease when taken daily in an oral form.